TheraGenetics (London/Cambridge, Massachusetts), a personalized medicine company, is developing genetic-based tests to help improve the treatment of central nervous system disorders including depression and schizophrenia and is now part of a consortium to identify biomarkers for Alzheimer's disease. (Diagnostics & Imaging Week)